|Day Low/High||62.39 / 65.25|
|52 Wk Low/High||48.27 / 86.58|
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Aggressive traders could go long here.
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
The U.S. Food and Drug Administration approved the biotech company's treatment for spinal muscular atrophy late Friday.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results.
Lots of energy names facing the potential for lower prices.
That may be the best way to get through the notorious month of August.
Stocks break free of range-bound trading by late morning as gains in biotech help to offset losses in energy.
The essence of sloppiness is to let it all ride, so look at your portfolio and decide what has moved too much and what you should take off.
5 biotech stocks that could outperform the overall market in 2016.